NCT06343714View on ClinicalTrials.gov

A Study of FB1003 in Healthy and Osteoarthritis Pain Subjects

PHASE1RecruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

April 7, 2024

Primary Completion Date

February 28, 2026

Study Completion Date

May 30, 2026

Conditions
Healthy Volunteers
Interventions
DRUG

FB1003

Subcutaneous (SC) injection

DRUG

Placebo

Subcutaneous (SC) injection

Trial Locations (2)

3153

RECRUITING

Veritus Research, Bayswater

4006

COMPLETED

Nucleus Network, Brisbane

Sponsors
All Listed Sponsors
lead

4B Technologies Limited

INDUSTRY